o.pasquale
TL1 Member · Dijon, FR
Newer member working through the reference pages before asking anything.
Joined 9 November 2025 · last posted 13h
30Posts here
1Topics
2Solutions
113Likes received
146Likes given
13Badges
115Days visited
1.1kPosts read
Recent activity
Full stream-
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #44 · Pharmacology › Formulation chemistry · 27 Jul 2026 · 0 likes Having read the whole Solubility limits thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #91 · Practice › Interactions · 22 Jul 2026 · 12 likes Taking post #90 at face value and following it one step further. Separation timing versus clinically important interaction: a separation timing inconvenience (taking…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #58 · Practice › Dosing & titration · 12 Jul 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
A critique that turned out to be unfair, retracted by its author Replied, post #24 · Evidence › Study critique · 4 Jul 2026 · 5 likes Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question.…
-
Journal club: what we got wrong in an earlier session Replied, post #24 · Evidence › Journal club · 23 Jun 2026 · 0 likes On post #22 — agreed on the reasoning, with one qualification. Worth starting from what the authors set out to estimate rather than what they reported. Half the…
-
Joined after a search result and stayed Replied, post #7 · Lounge › Introductions · 20 Jun 2026 · 24 likes Coming in from the clinical side and slightly wary of the register. I have read enough to see that "not medical advice" is meant here rather than pasted, which is why I…
-
Follow-up: Reading an interaction checker output critically Replied, post #11 · Practice › Interactions · 19 Jun 2026 · 30 likes Following this. I have the same question and no better information than the first post.
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #8 · marked as the solution · Compounds › Cagrilintide & amylin analogues · 13 Jun 2026 · 6 likes Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here. Small…
-
Prescription requirements and telehealth models — a second dataset Replied, post #22 · Sourcing › Regulatory · 7 May 2026 · 10 likes Answering the Prescription requirements and telehealth models question as asked, then the question I think is meant. As asked: yes, with the qualification below. As…
-
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #91 · Lounge › Introductions · 17 Mar 2026 · 0 likes If you are arriving from somewhere louder, the pace here will feel slow. A topic can sit for two days and then get a reply that is worth the wait. That is the design…
-
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #123 · Compounds › Semaglutide · 19 Feb 2026 · 7 likes An honest declaration on semaglutide half-life: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
-
Comparing my trajectory with the trial curves, carefully — a second dataset Started this topic · Outcomes › Progress reports · 14 Jan 2026 · 47 likes Comparing my trajectory with the trial curves, carefully — a second dataset — setting out what I have, and where I think it stops being reliable. Maintenance rather…